Sarcoma with BCOR genetic alterations is an uncommon cancer that develops most often in bone and less often in the soft tissues. It belongs to a group called undifferentiated round cell sarcomas, meaning the tumor cells look very immature and do not resemble any normal tissue under the microscope. It accounts for roughly 4 percent of that group.
Your report may use one of several names. BCOR-CCNB3 sarcoma names the commonest form, in which the BCOR gene is joined to a gene called CCNB3. Sarcoma with BCOR genetic alterations is the current name for the whole group, which also includes tumors carrying a different kind of change in the same gene. Older reports may say Ewing-like sarcoma, a term no longer used.
This article explains what appears on the pathology report, why this tumor is separated from Ewing sarcoma despite looking similar, and why the molecular testing can be difficult.
Most tumors in this group arise in bone, which distinguishes them from CIC-rearranged sarcoma, the other main round cell sarcoma, which favors soft tissue. The commonest sites are the long bones of the legs and arms, usually toward the middle of the bone, and the pelvis. On an X-ray, the tumor typically eats into the bone while the outer shell thickens around it.
The average age at diagnosis is around 15, and the tumor occurs about three times as often in boys and young men as in girls and young women. That imbalance is no coincidence: the responsible genetic change sits on the X chromosome, as explained below.
Symptoms are essentially the same as for Ewing sarcoma and osteosarcoma, which is part of why imaging and a biopsy are needed to tell them apart.
These tumors are caused by a change in the BCOR gene acquired during life within the tumor cells. They are not inherited, are not passed to children, and carry no implications for relatives.
BCOR normally helps switch other genes off at the right times. When it is altered, that control is lost, and genes that drive cell division are switched on when they should be quiet. The result is the same regardless of the change, which is why the World Health Organization groups them.
Tumors with BCOR genetic alterations fall into two groups that differ in the change involved and in who develops them. Your report will usually make clear which applies.
Less commonly, BCOR is joined to other partner genes such as MAML3. A related change involving BCOR is also found in high-grade endometrial stromal sarcoma, a tumor of the uterus. That is a different disease which happens to involve the same gene.
Diagnosis requires imaging, microscopic examination, immunohistochemistry, and molecular testing together. None of them is sufficient.
Under the microscope, the tumor contains a mixture of round cells and spindle-shaped cells, often arranged in whorls. This mixture is a useful clue, because Ewing sarcoma is usually made of round cells alone. The background frequently has a gel-like, or myxoid, quality, and the tumor contains a fine network of branching blood vessels. The nuclei tend to have pale chromatin and inconspicuous nucleoli.
One further difference is worth knowing. The proportion of dividing cells, measured as the Ki-67 index, is typically much lower here than in Ewing sarcoma. A report describing a round cell sarcoma with a surprisingly low Ki-67 may prompt testing for a BCOR alteration.
As with the other bone sarcomas, where the biopsy is taken from matters, the needle track has to be removed with the tumor at the definitive operation, so the biopsy is best performed at the center that will carry out the surgery.
Immunohistochemistry uses antibodies to detect proteins in the tumor cells. It does a great deal in this diagnosis because molecular testing is unreliable, as explained below.
Molecular testing looks for the BCOR alteration directly, and it is harder than for most fusion-driven sarcomas.
The reason is the nature of the change. BCOR and CCNB3 sit only a short distance apart on the same chromosome. The fusion is created when a piece of that chromosome flips around rather than breaking away entirely. FISH is designed to detect a gene breaking apart and moving, so it performs poorly when two neighboring genes change orientation.
RNA sequencing, usually part of a next-generation sequencing panel, is the more reliable method and can name the fusion directly. Internal tandem duplications require a test that can detect a repeated stretch within a gene, which not every panel does.
Because of these limitations, a positive CCNB3 or BCOR stain in a tumor with the right appearance carries real weight. A negative FISH result does not by itself rule out the diagnosis. If your report describes a round cell sarcoma without a confirmed genetic result, it is reasonable to ask which tests were used and whether RNA sequencing was among them.
This tumor is one of four diseases that look similar under the microscope and were once grouped as Ewing-like sarcomas. The World Health Organization classification of soft tissue and bone tumors, 5th edition, published in 2020, separated them.
Of the three non-Ewing entities, this one behaves most like Ewing sarcoma and is treated most similarly. That’s meaningful information for someone who has read about the group as a whole and found a discouraging picture.
A margin is the edge of tissue the surgeon cuts to remove the tumor. The pathologist inks these edges and examines them under the microscope. A negative margin means no tumor cells were seen at the edge. A positive margin means the tumor reaches the edge and some may have been left behind.
Negative margins lower the risk of the tumor returning in the same place, and margin status influences whether radiation is added. Perineural and lymphovascular invasion are uncommon in this tumor and are noted only when present.
These tumors are staged using the system for the bone or soft tissue site where they arise. It takes account of the size of the tumor, lymph node involvement, and spread to distant sites. The lungs are the commonest site of spread.
No grade is given. Round cell sarcomas are high grade by definition, in the same way that Ewing sarcoma is not graded, so a report without a grade is expected rather than incomplete.
As with the other round cell sarcomas, what matters far more than the stage number is whether the disease is confined to one place or has already spread.
Outcomes are better than for CIC-rearranged sarcoma and broadly comparable to Ewing sarcoma. That is the most useful thing to know if you have been reading about round cell sarcomas generally.
In a published series, roughly 75 percent of patients were alive five years after diagnosis and roughly 56 percent at ten years. Tumors in the arms and legs did better than those in the spine, pelvis, or soft tissue. These figures come from small numbers of patients, because the entity has only been recognized since 2012, and they should be read with that in mind.
Features associated with a less favorable outcome include spread at diagnosis, a tumor in a central rather than a limb location, and a positive surgical margin. Your sarcoma team can give figures that match your situation.
A sarcoma team at a center that treats these tumors regularly should guide care. Because the diagnosis is uncommon and difficult, a sarcoma-specialist pathologist usually reviews the slides, and it is reasonable to ask whether that has happened.
Treatment follows the approach used for Ewing sarcoma. Chemotherapy is given first, over several months, to shrink the tumor and treat any microscopic spread. Surgery, radiation, or both then treat the original tumor, and more chemotherapy follows. Responses to Ewing-type chemotherapy are generally good, which is one of the main practical differences from CIC-rearranged sarcoma.
Follow-up continues for years, with imaging of the original site and of the chest. It also covers the long-term effects of treatment on the heart, fertility, growth, and the risk of a second cancer later in life.